Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precigen

3.97
+0.02500.63%
Volume:355.38K
Turnover:1.40M
Market Cap:1.40B
PE:-9.23
High:4.02
Open:3.95
Low:3.91
Close:3.94
52wk High:5.23
52wk Low:0.6513
Shares:353.00M
Float Shares:205.00M
Volume Ratio:0.54
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4294
EPS(LYR):-0.4715
ROE:-668.03%
ROA:-67.44%
PB:-38.06
PE(LYR):-8.41

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Xcel Energy, Opendoor Technologies, Advance Auto Parts

Reuters
·
Aug 16

Crude Oil Down 1%; US Retail Sales Rise 0.5% In July

Benzinga
·
Aug 16

Precigen Up Nearly 67%, On Pace For Largest Percent Increase Since June 2020 -- Data Talk

Dow Jones
·
Aug 15

Precigen Shares up 41.6% After US FDA Approves Its Immunotherapy for Rare Respiratory Disease

THOMSON REUTERS
·
Aug 15

Precigen Raised to Neutral From Underweight by JP Morgan

Dow Jones
·
Aug 15

AquaBounty Technologies Announces Resignation of General Counsel Angela Olsen

Reuters
·
Aug 15

HC Wainwright Adjusts Price Target on Precigen to $8.50 From $6, Maintains Buy Rating

MT Newswires Live
·
Aug 15

Precigen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 15

Precigen, Inc. : H.c. Wainwright Raises Target Price to $8.5 From $6

THOMSON REUTERS
·
Aug 15

JPMorgan Upgrades Precigen to Neutral From Underweight

MT Newswires Live
·
Aug 15

Precigen Shares Surge More Than Double After US FDA Approves Its Immunotherapy for Rare Respiratory Disease, Last up 102% Premarket

THOMSON REUTERS
·
Aug 15

BRIEF-Precigen Announces Full FDA Approval Of Papzimeos

Reuters
·
Aug 15

US FDA approves Precigen's immunotherapy for rare respiratory disease

Reuters
·
Aug 15

Precigen Inc. Secures FDA Approval for PAPZIMEOS, Offering New Hope to Adult RRP Patients

Reuters
·
Aug 15

Precigen Announces Full FDA Approval of Papzimeos (Zopapogene Imadenovec-Drba), the First and Only Approved Therapy for the Treatment of Adults With Recurrent Respiratory Papillomatosis

THOMSON REUTERS
·
Aug 15

FDA: on Aug 14, FDA Approved First Immunotherapy for Recurrent Respiratory Papillomatosis

THOMSON REUTERS
·
Aug 15

U.S. RESEARCH ROUNDUP-Applied Materials, Precigen, Transdigm Group

Reuters
·
Aug 15

Precigen Gets FDA Approval of Respiratory-Tumor Treatment

Dow Jones
·
Aug 15

Precigen Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Aug 08

AquaBounty Q2 net loss narrows to $3.4 mln

Reuters
·
Aug 05